CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Goserelin Acetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04203212
NCT04203212N/ACompleted

Bone Mineral Density Alterations and Correlations With Bone and Muscle Metabolism Parameters During Menstrual Cessation Due to GnRH Therapy and After Menstrual Restoration

424 General Military Hospital·observational·Posted Dec 18, 2019·Updated Jan 12, 2021

In Brief

An observational study evaluating Goserelin Acetate for Endometriosis and 3 related conditions. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The investigators aim to investigate the effect of menstrual cessation in women with endometriosis treated with GnRH analogs for 6 months on bone mineral density and bone and muscle metabolism parameters and subsequently the effects of menstrual restoration after GnRH analogs discontinuation on the above measured parameters

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 18, 2019
Enrollment StartOct 1, 2019
Primary CompletionDec 1, 2020
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.5 years ago

Interventions

Goserelin Acetatedrug

Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months